KemPharm Inc. (NASDAQ:KMPH) dropped 11.1% during mid-day trading on Tuesday . The stock traded as low as $3.75 and last traded at $3.77, with a volume of 76,141 shares traded. The stock had previously closed at $4.24.

KMPH has been the topic of several recent research reports. Canaccord Genuity restated a “buy” rating on shares of KemPharm in a research report on Tuesday, May 3rd. Oppenheimer Holdings Inc. restated a “buy” rating and set a $11.00 target price on shares of KemPharm in a research report on Tuesday, June 14th. Royal Bank Of Canada restated a “buy” rating on shares of KemPharm in a research report on Sunday, May 8th. Finally, Zacks Investment Research downgraded KemPharm from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $26.80.

The stock’s market cap is $55.49 million. The firm has a 50-day moving average of $4.70 and a 200-day moving average of $11.56.

KemPharm (NASDAQ:KMPH) last posted its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.26. Equities analysts expect that KemPharm Inc. will post ($2.79) EPS for the current year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.